Clinical study of intravitreal injection of conbercept in the treatment of retinopathy of prematurity

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066940

Enrollment

Unknown

Registered

2022-12-21

Start date

2018-06-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

Control group:laser

Intervention group:Intravitreal injection of conbercept

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Infants with ROP (birth weight = 2000 g or gestational age = 32 weeks) in zone II stage 2 + and zone II stage 3 + who met the Chinese guidelines for screening retinopathy of prematurity were informed by a parent or guardian.

Exclusion criteria

Exclusion criteria: 1) Infants with congenital systemic malformations or congenital ocular malformations. 2) Infants who cannot be treated with conventional laser because of refractive stromal opacity. 3) Some parents or guardians refused to sign informed consent. 4) Rop4 or rop5 lesions 5) He has received any of the following treatments: retinal laser therapy; intravitreal anti VEGF therapy; cryotherapy; eye surgery, etc

Design outcomes

Primary

Measure	Time frame
Proportion of eyes with inactive retinopathy of prematurity and no dysplasia;	—

Secondary

Measure	Time frame
proportion of eyes with ocular AEs;	—

Countries

China

Contacts

Public ContactJianhong Liang

drliangjianhong@126.com13811366843

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026